Library›Substances and pharmacology›Synaptogenesis Neuroplasticity and Brain Rewiring

Synaptogenesis Neuroplasticity and Brain Rewiring

Synaptogenesis, Neuroplasticity, and Brain Rewiring examines the modern paradigm shift in psychopharmacology from chemical suppression toward active structural remodeling of neural circuits. Highlighting the molecular cascades of psilocybin and ketamine therapy, the activation of BDNF and mTOR pathways, the dissolution of the Default Mode Network (DMN), and the reversal of addiction and depression, this monograph bridges clinical psychedelic science with the Van Kush Family Research Institute's foundational *Building Brains* and *Neurogenesis, Neuroprotectants, and Synaptogenesis* research corpus.

The Paradigm Shift: From Suppression to Structural Remodeling

For over six decades, clinical psychiatry relied on the "monoamine deficiency" hypothesis—the premise that depression, anxiety, and trauma represent a chemical shortage of serotonin, dopamine, or norepinephrine that must be rectified with daily reuptake inhibitors:

<code>

[ THE CLINICAL PARADIGM REVOLUTION ]

│

┌──────────────────────────┴──────────────────────────┐

▼ ▼

[ OLD PARADIGM: CHEMICAL SUPPRESSION ] [ NEW PARADIGM: SYNAPTIC REWIRING ]

• "Monoamine deficiency" hypothesis • Neuroplasticity & synaptogenesis failure

• Chronic daily reuptake blockade (SSRIs) • Episodic structural remodeling (Psilocybin / Ketamine)

• Blunts emotional affect & symptoms • Sprouts new dendritic spines & connections

• Leaves frozen trauma loops intact • Resets the hyper-rigid Default Mode Network (DMN)

</code>

The Pathology of Atrophy: Modern high-resolution neuroimaging and post-mortem histology demonstrate that chronic stress, major depression, and PTSD are not mere chemical deficits; they are marked by structural neuro-architectural atrophy. Prolonged exposure to elevated cortisol and inflammatory cytokines causes the retraction of dendrites, the loss of synaptic spines in the prefrontal cortex (PFC) and hippocampus, and the overgrowth of fear circuits in the basolateral amygdala.
Rewiring vs. Numbing: Traditional psychiatric sedatives (benzodiazepines, antipsychotics) and SSRIs suppress symptom expression without rebuilding lost synaptic connections. In contrast, modern neuroplastic therapies actively stimulate synaptogenesis—the rapid sprouting of new dendritic spines and synaptic junctions—allowing entrenched, pathological neural loops (nicotine addiction, depressive despair, trauma flashbacks) to be structurally rewired.

Psilocybin (Mushroom) Therapy and the Serotonergic Plasticity Cascade

The active entheogenic alkaloid in sacred mushrooms (Psilocybe cubensis), psilocybin, is dephosphorylated in the body into psilocin (4-OH-DMT). Rather than merely elevating serotonin levels, psilocin acts as a powerful molecular catalyst for structural neuroplasticity:

<code>

[ Psilocin (4-OH-DMT) ]

│

▼ High-Affinity Agonism

[ Cortical Layer V Pyramidal Neurons: 5-HT2A & TrkB Receptors ]

│

├──────────────────────────────────────────────┐

▼ ▼

[ Calcium Influx (Ca2+) ] [ Direct TrkB Transactivation ]

│ │

▼ ▼

[ Exocytosis of BDNF ] ────────────────────────► [ PI3K / Akt Kinase Pathway ]

(Brain-Derived Neurotrophic Factor) │

▼

[ mTORC1 Complex Activation ]

│

▼

[ RAPID DENDRITIC SPINE MORPHOGENESIS ]

• Sprouting of new synaptic spines

• Increased synaptic density within 24h

• Re-opening of critical learning windows

</code>

1. The TrkB-BDNF-mTORC1 Pathway

Direct TrkB Binding: Landmark structural biology (Moliner et al., 2023) demonstrated that psychedelic molecules, including psilocin and LSD, bind directly to the transmembrane domain of TrkB (tropomyosin receptor kinase B)—the receptor for Brain-Derived Neurotrophic Factor (BDNF)—with an affinity 1,000 times higher than classic antidepressants.
mTORC1 Translation: TrkB activation triggers the downstream phosphorylation of the mTORC1 (mechanistic target of rapamycin complex 1) pathway. mTORC1 acts as the master cellular switch for local dendritic protein synthesis, driving the rapid construction of actin microfilaments and synaptic scaffolding proteins (PSD-95).
Spine Morphogenesis: In two-photon in vivo imaging studies (Ly et al., 2018; Shao et al., 2021), a single administration of psilocybin induced a persistent ~10% increase in dendritic spine density and spine head size in the prefrontal cortex, with new connections visible within 24 hours and persisting for months.

2. Default Mode Network (DMN) Reset: Breaking Addiction and Rumination

The Default Mode Network (DMN) is a high-level interconnected brain network (comprising the medial prefrontal cortex, posterior cingulate cortex, and angular gyrus) that orchestrates self-reflection, ego identity, internal monologue, and autobiographical memory.
The Hyper-Rigid DMN: In major depression and addiction, the DMN becomes pathologically hyper-active and hyper-coherent. The brain is trapped in rigid, repetitive loops of self-criticism, existential despair, and compulsive craving.
Entropy and De-synchronization: Psilocybin dramatically desynchronizes DMN firing, collapsing functional modularity and increasing global neural entropy. The brain enters a hyper-connected state where brain regions that rarely communicate begin cross-talking directly.
Smoking Cessation (The Matthew Johnson Trials): In Johns Hopkins clinical trials led by Dr. Matthew Johnson, psilocybin-assisted psychotherapy achieved unprecedented 67–80% smoking cessation abstinence rates at 6-month and 12-month follow-ups—materially outperforming every existing pharmaceutical (nicotine patches, bupropion, varenicline). By dismantling the DMN, psilocybin decoupled the cue-craving reflex, allowing patients to step outside their conditioned self-identity as "a smoker" and instantly rewire behavioral choices.

Ketamine Therapy and Glutamatergic Synaptogenesis

Originally developed as a dissociative surgical anesthetic, ketamine is an arylcyclohexylamine that induces rapid, robust antidepressant effects in patients with treatment-resistant depression within two to four hours of administration:

<code>

[ Sub-Anesthetic Ketamine ] ──► [ Blocks NMDAR on Cortical GABAergic Interneurons ]

│

▼ Disinhibition

[ Burst of Presynaptic Glutamate Release ]

│

▼ Stimulation

[ Postsynaptic AMPA Receptors ]

│

▼ Depolarization

[ L-Type Voltage-Gated Ca2+ Channels ]

│

▼ Activity-Dependent

[ Massive BDNF Exocytosis ]

│

▼

[ Rapid mTORC1 Translation ]

│

▼

[ RESTORATION OF ATROPHIED SYNAPSES (2-4 HOURS) ]

</code>

1. The Interneuron Disinhibition Hypothesis

Ketamine is an uncompetitive open-channel blocker of the NMDA (N-methyl-D-aspartate) receptor.
At low, sub-anesthetic doses (e.g., $0.5\text{ mg/kg}$ IV over 40 minutes), ketamine exhibits high selectivity for NMDA receptors located on inhibitory GABAergic interneurons.
Because these interneurons fire tonic baseline inhibitory signals onto excitatory pyramidal neurons, blocking their NMDARs removes the brake: it disinhibits pyramidal neurons, triggering a transient, high-amplitude burst of presynaptic glutamate release.

2. The AMPA-to-mTORC1 Burst

The dumped glutamate floods synaptic clefts and binds post-synaptic AMPA receptors, causing rapid sodium and calcium influx.
This intense post-synaptic depolarization stimulates voltage-gated calcium channels, triggering the activity-dependent release of BDNF.
BDNF activates TrkB and stimulates the mTORC1 pathway, driving de novo synthesis of synaptic proteins (such as GluA1 AMPA receptor subunits and synapsin).
Within two to four hours—long before traditional monoamine antidepressants produce even initial neurochemical changes—ketamine physically restores synapses that had atrophied from years of depressive stress, abruptly silencing suicidal ideation.

The Triad: Neurogenesis, Synaptogenesis, and Neuroprotection

The Van Kush Family Research Institute's 2016 Church of Neuroscience research series (*Building Brains* and *Neurogenesis, Neuroprotectants, and Synaptogenesis*) formulated brain repair around three interdependent pillars:

{| class="wikitable"

! Mechanism !! Definition !! Anatomical Locus !! Primary Biological Drivers !! Key Studied Molecules

| Neurogenesis || The birth, proliferation, and functional integration of entirely new neurons from neural stem cells. || Subgranular zone (SGZ) of the hippocampal dentate gyrus; subventricular zone (SVZ). || Exercise, enriched environments, BDNF, endocannabinoid CB1 signaling, $5\text{-HT}_{2A}$ agonism. || 2-AG, 8-Prenylnaringenin, Psilocin, Aerobic running.

| Synaptogenesis || The formation, arborization, and stabilization of new dendritic spines and synaptic connections between existing neurons. || Cerebral cortex (Layers II–V), hippocampus, amygdala, striatum. || TrkB activation, BDNF release, mTORC1 signaling, AMPA receptor potentiation. || Ketamine, Psilocin, LSD, Ampakines (Aniracetam, CX-614), CX-516.

| Neuroprotection || Shielding vulnerable nervous tissue from ischemic, mechanical, toxic, and excitotoxic injury. || Universal across central and peripheral nervous system. || Microglial anti-inflammatory modulation, calcium buffering, antioxidant defenses, inhibition of excitotoxicity. || 2-AG, Anandamide, Carnosine, Cycloastragenol, Cannabidiol (CBD).

1. Distinguishing Neurogenesis from Synaptogenesis

Neurogenesis: The adult mammalian brain does not generate new neurons indiscriminately; active adult neurogenesis is restricted to specific neurogenic niches, primarily the hippocampus (dentate gyrus). While essential for learning new spatial patterns and emotional resilience, neurogenesis is a slow process requiring weeks for neural precursor cells to migrate and mature.
Synaptogenesis: Synaptogenesis occurs throughout the entire neocortex within minutes to hours. A patient does not need to grow a billion new brain cells to overcome depression or stop smoking; they need to re-wire the synaptic connections linking their existing 86 billion neurons.

2. Glial Architecture: The Astrocytes and Oligodendrocytes

As highlighted in the foundational *Building Brains* research (citing Marian Diamond's anatomical discovery that Albert Einstein's brain possessed a significantly higher glia-to-neuron ratio in the prefrontal and parietal cortex):

Astrocytes (The Synaptic Regulators): Astrocytes are not passive scaffolding; they form the "tripartite synapse," actively clearing excess glutamate via GLT-1 transporters to prevent excitotoxicity, providing lactate fuel to working neurons, and regulating adenosine sleep pressure.
Oligodendrocytes and Remyelination: Oligodendrocytes wrap axon cables in lipid-rich myelin sheaths, enabling rapid saltatory action potential conduction. In neurodegenerative disease and severe trauma, remyelination failure leaves axons exposed. The over-the-counter antihistamine clemastine was identified in cellular screens as an agent promoting oligodendrocyte precursor cell differentiation and active axon remyelination.

3. Ampakines and Dendritic Arborization

First synthesized by Dr. Gary Lynch at UC Irvine, ampakines (such as aniracetam, CX-516, and CX-614) are positive allosteric modulators of AMPA receptors.
By slowing AMPA receptor deactivation and desensitization, ampakines increase the amplitude of excitatory post-synaptic currents without inducing the excitotoxic cell death caused by direct glutamate agonists.
Ampakines stimulate local BDNF release, promoting sustained dendritic branch elongation and long-term potentiation (LTP)—acting as non-psychedelic chemical facilitators of synaptogenesis.

4. Endocannabinoid Neuroprotection: 2-AG and Brain Trauma

The endocannabinoid 2-Arachidonoylglycerol (2-AG) functions as the brain's native on-demand circuit breaker.
In traumatic brain injury (TBI), stroke, and cerebral edema, neurons dump catastrophic levels of glutamate, triggering fatal calcium overload (excitotoxicity).
In response to excessive depolarization, post-synaptic neurons synthesize massive surges of 2-AG from membrane lipids. 2-AG travels retrogradely across the synapse to activate presynaptic $\text{CB}_1$ receptors, physically shutting down further glutamate release and reducing brain swelling (edema).
Enhancing endogenous 2-AG signaling via MAGL inhibition provides profound neuroprotection, underscoring why the endocannabinoid system sits at the core of the brain-repair triad.

Filed under Substances and pharmacology Organic chemistry and synthesis